Peripheral T Cell Lymphoma NOS: Understanding Your Pathology Report

By Jason Wasserman MD PhD FRCPC
April 21, 2026

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), is an aggressive blood cancer that starts in mature T cells — the white blood cells that normally coordinate immune responses, help fight infections, and regulate the immune system. The word “peripheral” does not mean the cancer is located at the edges of the body; it means the lymphoma arises from mature T cells that have already completed their development in the thymus (the organ where T cells are formed) and circulate in the lymph nodes, blood, and tissues. “Not otherwise specified” (NOS) means that after thorough testing, this lymphoma does not fit the criteria for any of the other recognized specific subtypes of T cell lymphoma — it is therefore what pathologists call a diagnosis of exclusion. Before this diagnosis is made, a comprehensive panel of tests is performed to rule out AITL, ALCL, extranodal NK/T cell lymphoma, adult T cell leukemia/lymphoma, and other defined T cell lymphoma types. PTCL-NOS is the most common peripheral T cell lymphoma subtype, accounting for approximately 25–30% of all T cell lymphomas, and is found in patients worldwide. This article will help you understand the findings in your pathology report, what each term means, and why it matters for your care.

What are the symptoms of peripheral T cell lymphoma NOS?

PTCL-NOS typically presents with rapidly enlarging, painless swollen lymph nodes — most commonly in the neck, armpits, or groin. Because the disease frequently involves sites outside the lymph nodes (extranodal disease), symptoms may also reflect involvement of the liver (causing discomfort in the right upper abdomen or jaundice), spleen (causing fullness or discomfort in the left upper abdomen), bone marrow (causing fatigue, easy bruising, or increased infections from low blood counts), or skin (causing nodules, lumps, or ulcers). Involvement of the gastrointestinal tract can cause abdominal pain, bleeding, or diarrhea.

General constitutional symptoms — called B symptoms — are very common and may be prominent at presentation. These include fever (particularly persistent or recurrent fevers without obvious infection), drenching night sweats, and significant unintentional weight loss of more than 10% of body weight over six months. Fatigue is also common. Some patients experience intense generalized itching (pruritus) or develop elevated blood eosinophils — a phenomenon related to immune proteins released by lymphoma cells, called cytokines.

In rare cases, a serious complication called hemophagocytic lymphohistiocytosis (HLH) can develop, in which the immune system becomes dangerously overactivated and begins destroying the body’s own blood cells. HLH causes high fevers, enlarged liver and spleen, very low blood counts, and can be life-threatening; it requires urgent recognition and treatment.

Because PTCL-NOS is aggressive and symptoms can worsen rapidly over weeks, prompt medical evaluation, biopsy, and treatment are important.

What causes peripheral T cell lymphoma NOS?

The exact causes of PTCL-NOS are not fully understood. The lymphoma arises from acquired genetic changes in a single mature T cell — changes that accumulate over a person’s lifetime rather than being inherited — that allow the cell to survive and proliferate abnormally, producing a population of identical abnormal T cells (a clone). No specific trigger is identified in most cases.

Certain factors are associated with an increased risk. Epstein-Barr virus (EBV) is found inside the lymphoma cells in a subset of PTCL-NOS cases and may contribute to lymphoma development in those cases. A weakened immune system — from HIV infection, organ transplantation, or other causes — increases the overall risk of T cell lymphomas. In patients with autoimmune diseases treated with immunosuppressive therapies, particularly methotrexate, a small number of cases of lymphoma, including PTCL-NOS, have been reported, and reducing immunosuppression can sometimes cause regression.

Recent molecular research has identified two major biological groups within PTCL-NOS based on which T cell regulatory proteins the lymphoma cells most resemble. Cases resembling a T helper cell type driven by a protein called GATA3 tend to behave more aggressively, while cases resembling a different T helper cell type driven by a protein called TBX21 tend to have a somewhat more favorable course. These molecular groups are beginning to appear in some pathology reports and are an area of active research that may eventually guide more tailored treatment approaches.

How is the diagnosis made?

The diagnosis of PTCL-NOS requires tissue examination under the microscope and cannot be made on blood tests, imaging, or clinical findings alone. An excisional biopsy — removal of an entire lymph node — is strongly preferred, because the full architecture of the node is needed to characterize the growth pattern and to perform the comprehensive testing required. Core needle biopsy is used when an excisional biopsy is not accessible, though it provides less tissue and can make the complete evaluation more difficult.

Once the tissue is obtained, the pathologist performs an extensive panel of tests: immunohistochemistry (IHC) to characterize the protein expression profile of the cells; flow cytometry to analyze cell surface proteins in detail; and T cell receptor (TCR) gene rearrangement testing to confirm that the T cells are clonal (derived from a single abnormal cell). The diagnosis of PTCL-NOS is established only after this testing excludes all other defined T cell lymphoma subtypes — including angioimmunoblastic T cell lymphoma, ALK-positive and ALK-negative anaplastic large cell lymphoma, extranodal NK/T cell lymphoma, adult T cell leukemia/lymphoma, and others. For this reason, the pathology report for PTCL-NOS often documents not only which proteins are present but also which other diagnoses were considered and excluded.

Once the tissue diagnosis is established, staging evaluation includes PET/CT imaging, blood tests including LDH and a complete blood count, bone marrow biopsy, and, in some cases, cerebrospinal fluid examination. HIV and HTLV-1 testing is recommended for all newly diagnosed T cell lymphoma patients, because HTLV-1 infection causes a distinct disease (adult T cell leukemia/lymphoma) that requires specific treatment.

What does peripheral T cell lymphoma NOS look like under the microscope?

PTCL-NOS has a wide range of appearances under the microscope — this variability is one of its defining characteristics and helps explain why it can be challenging to classify. The lymph node is typically effaced (the normal architecture is replaced) either partially or completely by abnormal T cells, which grow in sheets or diffuse collections through the T cell zones — the areas of the lymph node where T cells normally reside, called the paracortex.

The abnormal T cells themselves vary considerably in size and shape between cases. Most cases contain a mixture of medium- to large-sized cells with irregular or folded nuclei, prominent nucleoli (dense structures within the nucleus), and moderate amounts of pale cytoplasm (the material surrounding the nucleus). The cells show frequent mitotic figures — cells caught in the act of dividing — reflecting the aggressive, rapidly proliferating nature of the lymphoma. In some cases, small to medium-sized cells with clear cytoplasm dominate; in others, large cells predominate.

A characteristic microscopic feature of PTCL-NOS is the presence of prominent high endothelial venules (HEVs) — thickened, cuboidal blood vessels in the background of the tumor that are not normally prominent in a resting lymph node. Their presence is a helpful diagnostic clue and reflects the abnormal cytokine environment created by the lymphoma cells.

The tumor background typically contains a mixture of non-cancerous reactive immune cells — scattered small lymphocytes, plasma cells, eosinophils, histiocytes, and sometimes epithelioid histiocytes (histiocytes with a characteristic elongated, activated appearance). The composition of this reactive background varies between cases and does not significantly affect the diagnosis, but cases with many eosinophils in the background are often associated with EBV-positive tumor cells.

Immunohistochemistry results

Immunohistochemistry (IHC) is a laboratory test performed on biopsy tissue that uses specially prepared antibodies to detect specific proteins within cells. Each antibody produces a visible color change at its target protein, which the pathologist sees under the microscope. In PTCL-NOS, IHC serves several purposes: it confirms the T cell identity of the lymphoma cells; identifies which T cell subtype (helper vs. cytotoxic) the lymphoma most resembles; detects aberrant loss of proteins that are normally present on T cells (which supports the diagnosis of lymphoma over reactive conditions); and tests for markers — particularly CD30 — that have direct treatment implications. Each result is reported as positive (the protein is present) or negative (the protein is absent).

CD3 — Positive in most cases (may be reduced or absent in some). CD3 is the most reliable surface marker of T cells and confirms T cell origin. Its expression may be weaker than in normal T cells.
CD2, CD5, CD7 — Variable. These are additional T cell surface markers normally expressed on mature T cells. In PTCL-NOS, one or more of these markers is commonly absent or reduced — a finding called aberrant antigen loss. Aberrant antigen loss is an important clue that the T cells are neoplastic (cancerous) rather than normal, because normal T cells reliably express all of these markers. The specific pattern of loss is noted in the pathology report.
CD4 — Positive in most cases. CD4 is a marker of T helper cells — the subset of T cells that coordinate immune responses. The majority of PTCL-NOS cases are CD4-positive, reflecting their origin from helper T cells. Cases with very high CD4 expression often correspond to the GATA3 molecular subgroup.
CD8 — Positive in a minority of cases. CD8 is a marker of cytotoxic T cells — the subset of T cells that directly kill infected or abnormal cells. Most CD8-positive PTCL-NOS cases belong to the TBX21 molecular subgroup and may also express cytotoxic granule proteins (see below). Some cases express both CD4 and CD8, while others express neither.
TIA1, Granzyme B, Perforin — Variable. These are cytotoxic granule proteins — molecular weapons that cytotoxic T cells use to kill target cells. Their expression in the lymphoma cells indicates cytotoxic differentiation and is more common in CD8-positive cases. Cytotoxic marker positivity is noted in the report and is one of the features helping to assign the molecular subgroup.
CD30 — Positive in approximately 20–30% of cases, usually in a minority of the tumor cells rather than uniformly throughout. CD30 is one of the most clinically important IHC findings in PTCL-NOS because its presence can make patients eligible for brentuximab vedotin — an antibody-drug therapy that delivers chemotherapy directly to CD30-positive cells. A CD30-positive PTCL-NOS treated with brentuximab vedotin combined with CHP chemotherapy (BV-CHP) has better outcomes than standard CHOP in CD30-positive cases.
EBER — Variable. EBER in situ hybridization is performed to detect EBV inside the lymphoma cells. A positive T cell result identifies the case as EBV-associated PTCL-NOS.
ALK — Negative. ALK protein is the defining marker of ALK-positive anaplastic large cell lymphoma. Its absence in PTCL-NOS is part of how that diagnosis is excluded.
CD20, PAX5 — Negative. These B cell markers are absent, confirming the lymphoma is not of B cell origin.
Ki-67 — High, typically 40–80% or above, reflecting the aggressive and rapidly proliferating nature of this lymphoma.

T cell receptor (TCR) gene rearrangement testing

T cell receptor gene rearrangement testing — also called TCR clonality testing — is a molecular test performed on the biopsy tissue to determine whether the T cells in the sample are clonal (all derived from a single abnormal parent cell) or polyclonal (many different T cells, as would be expected in a normal immune response or reactive condition).

T cells normally generate enormous diversity in their T cell receptors — the surface proteins they use to recognize specific infections — through a process of controlled DNA rearrangement. This diversity means that in a healthy lymph node, T cells display thousands of different TCR gene configurations. In T cell lymphoma, all the malignant cells descend from a single transformed T cell and therefore carry an identical TCR gene rearrangement — a pattern called clonality. Detecting this clonal TCR rearrangement by PCR-based testing provides molecular evidence that a T cell population is neoplastic rather than reactive.

A clonal result supports the diagnosis of T cell lymphoma, but it is important to know that clonality alone does not confirm lymphoma — small clonal T cell populations can occasionally be found in benign conditions. Conversely, a polyclonal result does not rule out lymphoma if the clinical and pathological features are otherwise diagnostic. TCR clonality testing is therefore interpreted alongside the microscopic appearance and IHC results, not as a standalone test.

Staging

PTCL-NOS is staged using the Lugano classification (modified Ann Arbor system), based on PET/CT imaging and bone marrow biopsy. Because PTCL-NOS frequently involves multiple lymph node groups and extranodal sites at the time of diagnosis, the majority of patients present with advanced-stage (stage III or IV) disease.

Stage I — A single lymph node region or single extranodal site is involved.
Stage II — Two or more lymph node regions on the same side of the diaphragm, or one extranodal site with regional lymph node involvement.
Stage III — Lymph node regions on both sides of the diaphragm are involved.
Stage IV — Disseminated extranodal involvement, or involvement of bone marrow, liver, lung, or other distant organs.

Alongside stage, the Prognostic Index for T cell lymphomas (PIT score) is commonly used to estimate individual prognosis. The PIT score assigns points based on four factors: age over 60, performance status (ability to carry out daily activities), LDH level (a blood marker of cell turnover), and bone marrow involvement. Patients are divided into four risk groups, with median survival ranging from less than one year (the highest risk group) to more than six years (the lowest risk group) with standard chemotherapy.

What is the prognosis?

PTCL-NOS is an aggressive lymphoma with outcomes that are generally less favorable than most B cell lymphomas. Five-year overall survival rates are approximately 30–40% with standard first-line chemotherapy, though outcomes vary substantially by clinical features, molecular subtype, and treatment received. The GATA3 molecular subgroup has a worse prognosis than the TBX21 group, with five-year survival rates of approximately 20% and 40%, respectively, in published series.

Key factors associated with a worse prognosis include advanced stage (III–IV), high PIT score, elevated LDH, bone marrow involvement, poor performance status, and the GATA3 molecular subgroup. CD30 positivity, while it identifies patients eligible for brentuximab vedotin, does not by itself confer a better or worse prognosis — it is the availability of targeted treatment that makes CD30 testing clinically important.

The poor outcomes with standard CHOP-based chemotherapy have motivated significant research into more intensive first-line regimens, novel targeted therapies, and the incorporation of autologous stem cell transplantation in first remission for eligible patients. Outcomes continue to improve as new treatment options are developed.

What happens after the diagnosis?

Because PTCL-NOS is aggressive, treatment is typically started within one to two weeks of diagnosis. Most patients are referred to a hematologist or lymphoma oncologist with experience in T cell lymphomas.

For CD30-positive PTCL-NOS, the preferred first-line regimen is BV-CHP — brentuximab vedotin (an antibody-drug conjugate targeting CD30) combined with CHP chemotherapy (cyclophosphamide, doxorubicin, and prednisone, without vincristine). The ECHELON-2 trial demonstrated that BV-CHP improves progression-free and overall survival compared to standard CHOP in CD30-positive peripheral T cell lymphomas, making BV-CHP the standard of care for eligible patients. CD30 testing is therefore one of the first and most important results your care team will look for when planning treatment.

For CD30-negative PTCL-NOS, standard first-line treatment is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOEP (CHOP plus etoposide), the latter often preferred in younger, fit patients. However, outcomes with CHOP-based regimens are considerably worse in T cell lymphomas than in B cell lymphomas, and participation in clinical trials is strongly encouraged. More intensive induction regimens incorporating agents such as romidepsin (a histone deacetylase inhibitor) or pralatrexate are under investigation.

For patients who achieve complete remission after first-line chemotherapy and are fit enough, consolidation with autologous stem cell transplantation (using the patient’s own stem cells, collected before high-dose chemotherapy) is recommended at many centers to prolong remission, though evidence for benefit is ongoing. Allogeneic stem cell transplantation (using a donor’s stem cells) may be considered in selected patients, particularly at relapse.

For relapsed or refractory PTCL-NOS, options include romidepsin, pralatrexate, belinostat (all histone deacetylase or folate inhibitors), bendamustine, brentuximab vedotin (if CD30-positive), and participation in clinical trials evaluating checkpoint inhibitors and other novel agents. CAR T cell therapy is being investigated in T cell lymphomas but is not yet established as standard care.

If immunosuppressive therapy was a contributing factor (for example, methotrexate for an autoimmune disease), reducing or stopping immunosuppression may be considered as part of the treatment approach, in consultation with the specialist managing the underlying condition.

Questions to ask your doctor

Were all other specific T cell lymphoma subtypes tested for and excluded before this PTCL-NOS diagnosis was made?
Is my lymphoma CD30-positive, and am I eligible for BV-CHP rather than standard CHOP?
Was EBER testing performed to check whether EBV is present in the lymphoma cells?
Was HTLV-1 testing performed, and what was the result?
Was TCR clonality testing performed, and what was the result?
What molecular subgroup does my lymphoma belong to — GATA3 or TBX21 — and has this been assessed?
What stage is my lymphoma, and what is my PIT score?
What first-line treatment are you recommending, and is it BV-CHP, CHOP, or CHOEP?
Am I a candidate for autologous stem cell transplantation after achieving remission?
Are there clinical trials I should consider at this stage?
What symptoms between appointments should prompt me to contact you urgently?
What are the options if the lymphoma does not respond to or comes back after initial treatment?